GenoLogics Releases BioVault Biospecimen Management Software in Partnership with GenVault
News May 28, 2008
GenoLogics has announced its partnership with GenVault Corporation for its biospecimen data management system, BioVault.
“We recognize the significance of biospecimen repositories with well annotated clinical information to biomedical research and have embarked on a strategic endeavor to provide a full product line of integrated software systems”, says GenoLogics’ VP of Market Strategy, James DeGreef.
“We are excited about releasing our first biomedical product, BioVault, which is part of our total solution to help clients better manage their biosamples and related data”.
GenoLogics launched its Biomedical Informatics software solution to track observational studies, collect patient data at remote sites, provide biospecimen and clinical annotations management and facilitate researchers querying on clinical information and requesting samples. The suite is comprised of five integrated products, including BioVault for biospecimen management, which GenoLogics is partnering with GenVault, a vendor of biosample management solutions.
“Our experience with helping clients to stabilize their biosamples at room temperature and seamlessly manage their transport, storage and retrieval complements GenoLogics’ experience in providing lab and data management software solutions to research organizations”, says Dr. David Wellis, CEO of GenVault.
“Our biospecimen consumable, hardware and software technologies were built to allow for full integration with software applications such as the Biomedical Informatics products GenoLogics is building."
GenoLogics is developing their Biomedical Informatics product line as a complement to their existing Research Informatics product line. The biomedical and research product lines, combined with the ability to provide data warehouse services, enables GenoLogics to deploy an effective solution for clients to manage their translational research initiatives.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.